Korro Bio Inc. (KRRO) PT Lowered to $95 at RBC Capital

Go back to Korro Bio Inc. (KRRO) PT Lowered to $95 at RBC Capital

Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates

August 13, 2024 4:01 PM EDT


Regulatory filing of first-in-human (FIH) trial of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) anticipated in the second half of... More